// Workers AI · dad joke modeWhat did Guanabenz say to its friend? "Let's bond.
 | |
 | |
| Clinical data | |
|---|---|
| Trade names | Wytensin |
| AHFS/Drugs.com | Consumer Drug Information |
| MedlinePlus | a686003 |
| ATC code |
|
| Pharmacokinetic data | |
| Protein binding | 90% |
| Elimination half-life | 6 hours |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.023.410 |
| Chemical and physical data | |
| Formula | C8H8Cl2N4 |
| Molar mass | 231.08 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Guanabenz (pronounced GWAHN-a-benz, sold under the trade name Wytensin) is an alpha agonist that is selective to the alpha-2 adrenergic receptor. Guanabenz is used as an antihypertensive drug used in the treatment of high blood pressure (hypertension).[1][2]
The most common side effects during guanabenz therapy are dizziness, drowsiness, dry mouth, headache and weakness.[3]
Guanabenz can make one drowsy or less alert, therefore driving or operating dangerous machinery is not recommended.
Research
[edit]Guanabenz selectively binds a regulatory subunit of protein phosphatase 1, inhibiting stress-induced dephosphorylation of eIF2α and thereby prolonging activation of the integrated stress response.[4] This activity of Guanabenz is separate from its adrenergic activity and was proposed as a possible treatment against many neurodegenerative diseases, including amyotrophic lateral sclerosis.[5]
Guanabenz also been shown to have anti-inflammatory properties in different pathological situations, including multiple sclerosis.[6]
Guanabenz has also found to potentially slow down vanishing white matter disease (VWM).[7]
See also
[edit]References
[edit]- ↑ Walker BR, Hare LE, Deitch MW (1982). "Comparative antihypertensive effects of guanabenz and clonidine". The Journal of International Medical Research. 10 (1): 6–14. doi:10.1177/030006058201000102. PMID 7037502. S2CID 2139809.[permanent dead link]
- ↑ Bonham AC, Trapani AJ, Portis LR, Brody MJ (December 1984). "Studies on the mechanism of the central antihypertensive effect of guanabenz and clonidine". Journal of Hypertension. Supplement. 2 (3): S543–S546. PMID 6599714.[permanent dead link]
- ↑ "Guanabenz | The Merck Index Online". www.rsc.org. Retrieved 2023-04-17.
- ↑ Tsaytler P, Harding HP, Ron D, Bertolotti A (April 2011). "Selective inhibition of a regulatory subunit of protein phosphatase 1 restores proteostasis". Science. 332 (6025). New York, N.Y.: American Association for the Advancement of Science: 91–94. doi:10.1126/science.1201396. PMID 21385720.
- ↑ Dalla Bella E, Bersano E, Antonini G, Borghero G, Capasso M, Caponnetto C, et al. (October 2021). "The unfolded protein response in amyotrophic later sclerosis: results of a phase 2 trial". Brain. 144 (9): 2635–2647. doi:10.1093/brain/awab167. PMC 8557337. PMID 33905493.
- ↑ Way SW, Podojil JR, Clayton BL, Zaremba A, Collins TL, Kunjamma RB, et al. (March 2015). "Pharmaceutical integrated stress response enhancement protects oligodendrocytes and provides a potential multiple sclerosis therapeutic". Nature Communications. 6 6532. Bibcode:2015NatCo...6.6532W. doi:10.1038/ncomms7532. PMC 4360920. PMID 25766071.
- ↑ van der Knaap MS, Verbeek RJ, van Voorst RJ, Gonzato E, Stellingwerff MD, Voermans MM, et al. (September 2026). "Safety and efficacy of guanabenz in early-childhood onset vanishing white matter: primary analysis of a single-arm, phase 1/2 trial". The Lancet. Neurology. 25 (9): 818–829. doi:10.1016/S1474-4422(26)00241-3. PMID 42586097.